Quidel Corporation

QuidelOrtho Announces $300 Million Share Repurchase Authorization

Retrieved on: 
Wednesday, August 17, 2022
Data Management, Health, Technology, General Health, Research, Science, Biotechnology, U.S. Securities and Exchange Commission, Quidel Corporation, Growth, Private Securities Litigation Reform Act, Investment, Share repurchase, Ortho Clinical Diagnostics, Security (finance), Knowledge, Immunoassay, Transfusion medicine, Commission, Automation, Nature, NASDAQ, IVD, Nasdaq, Terminology, Medical device, Risk management

It also demonstrates our commitment to strategically return capital to shareholders, while investing in the long-term growth of the business.

Key Points: 
  • It also demonstrates our commitment to strategically return capital to shareholders, while investing in the long-term growth of the business.
  • The share repurchase authorization permits QuidelOrtho to repurchase, on a discretionary basis, up to $300 million of its outstanding shares of common stock in the open market or in privately negotiated transactions, subject to market conditions and other factors.
  • This share repurchase authorization does not obligate QuidelOrtho to repurchase any specific number of shares and may be suspended, modified, or terminated at any time without prior notice.
  • All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof.

ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW

Retrieved on: 
Tuesday, July 26, 2022
Knowledge, Immunoassay, Transfusion medicine, Customer integrated system, Quidel Corporation, Partnership, Informatics, IMV, IVD, Technology, Nasdaq, Ortho Clinical Diagnostics, Science, Automation, Management, Medicine, Medical device, Ortho

SAN DIEGO, July 26, 2022 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ: QDEL) ("QuidelOrtho") announced today that its subsidiary, Ortho Clinical Diagnostics, a leading provider of in vitro diagnostics solutions and services to hospitals, clinical laboratories and blood banks around the world, has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2022 IMV ServiceTrak™ Awards for the fifth consecutive year. The ranking is based on interviews conducted with laboratory professionals, including Ortho's customers, from more than 1,200 clinical testing locations operating over 1,900 collective instruments.   The prestigious annual IMV ServiceTrak™ Awards rankings affirm the continued power and impact of Ortho's innovative Ortho Care® Services and Informatics platform.

Key Points: 
  • Because of Ortho's culture of customer focus, the entire organization rallied to support customers during a difficult year."
  • Ortho Care Services and Informatics is the evolution of how service, expertise, technology and data-driven solutions come together to create a more effective, efficient lab, so labs can focus on improving patient outcomes.
  • The total offering consists of Ortho Care Intel, Ortho Care Ops, and Ortho Care Teams.
  • For more information about Ortho's award-winning Ortho Care Services and Informatics program, visit the Ortho Care Services and Informatics home page on Ortho's U.S. website or contact Ortho here .

ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW

Retrieved on: 
Tuesday, July 26, 2022
Knowledge, Immunoassay, Transfusion medicine, Customer integrated system, Quidel Corporation, Partnership, Informatics, IMV, IVD, Technology, Nasdaq, Ortho Clinical Diagnostics, Science, Automation, Management, Medicine, Medical device, Ortho

SAN DIEGO, July 26, 2022 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ: QDEL) ("QuidelOrtho") announced today that its subsidiary, Ortho Clinical Diagnostics, a leading provider of in vitro diagnostics solutions and services to hospitals, clinical laboratories and blood banks around the world, has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2022 IMV ServiceTrak™ Awards for the fifth consecutive year. The ranking is based on interviews conducted with laboratory professionals, including Ortho's customers, from more than 1,200 clinical testing locations operating over 1,900 collective instruments.   The prestigious annual IMV ServiceTrak™ Awards rankings affirm the continued power and impact of Ortho's innovative Ortho Care® Services and Informatics platform.

Key Points: 
  • Because of Ortho's culture of customer focus, the entire organization rallied to support customers during a difficult year."
  • Ortho Care Services and Informatics is the evolution of how service, expertise, technology and data-driven solutions come together to create a more effective, efficient lab, so labs can focus on improving patient outcomes.
  • The total offering consists of Ortho Care Intel, Ortho Care Ops, and Ortho Care Teams.
  • For more information about Ortho's award-winning Ortho Care Services and Informatics program, visit the Ortho Care Services and Informatics home page on Ortho's U.S. website or contact Ortho here .

QuidelOrtho to Report Second Quarter 2022 Financial Results on August 4, 2022

Retrieved on: 
Monday, July 18, 2022
Immunoassay, Automation, EDT, Interest, Nasdaq, Knowledge, Ortho Clinical Diagnostics, GLOBE, Transfusion medicine, Conference, IVD, NASDAQ, Quidel Corporation, Webcast, PDT, SAN, Medical device

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho), a leading in vitro diagnostics company, today announced it will report financial results for its second quarter 2022 ended July 3, 2022, after the market close on Thursday, August 4, 2022.

Key Points: 
  • SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho), a leading in vitro diagnostics company, today announced it will report financial results for its second quarter 2022 ended July 3, 2022, after the market close on Thursday, August 4, 2022.
  • Following the release of the financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss the financial results.
  • Interested parties can access the conference call on the Events & Presentations section of the Investor Relations page of QuidelOrthos website at https://ir.quidelortho.com/.
  • Our companys comprehensive product portfolio delivers accuracy, speed, automation and access, providing critical information when and where it is needed most.

Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County

Retrieved on: 
Wednesday, June 22, 2022
Technology, Biotechnology, Health, Other Philanthropy, Philanthropy, Research, Medical Devices, Software, General Health, Health Technology, Foundation, Science, Data Management, Cardiology, Degenerative disease, Disability, Cardiovascular disease, Science, Stroke, American Heart Association, Technology, Government, Torasemide, CEO, IVD, Knowledge, Immunoassay, Quidel Corporation, Research, Unitary state, Engineering, Heart failure, AHA, Ortho Clinical Diagnostics, NASDAQ, Health, Quality of life, Volunteering, Nasdaq, American Heart, Death, Twitter, Automation, Transfusion medicine, No, STEM, Friends, Prevalence, Goal, Risk, Organization, Pharmaceutical industry, Dietary supplement, Medical device, Woman, Facebook

Quidel Corporation will invest funding totaling $750,000 and support over the next three years as the American Heart Association approaches their centennial anniversary in 2024.

Key Points: 
  • Quidel Corporation will invest funding totaling $750,000 and support over the next three years as the American Heart Association approaches their centennial anniversary in 2024.
  • Heart disease is the leading cause of death in the U.S., and for many diseases such as heart failure, the prevalence is only increasing.
  • As we remain dedicated to addressing unmet needs in diseases, our top priority continues to be to elevate attention to heart disease.
  • Go Red for Women is the American Heart Associations national movement to increase womens heart health awareness and to improve the lives of women globally.

DGAP-News: QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS

Retrieved on: 
Thursday, June 9, 2022
Research, Awareness, Nasdaq, Physician, FDA, Patient, Infection, COVID-19, Education, Tick-Borne Disease Alliance, Pharmaceutical industry, Vaccine, Quidel Corporation, Lyme disease

Quidel is the nations leading developer of the only rapid point-of-care diagnostic Lyme disease test.

Key Points: 
  • Quidel is the nations leading developer of the only rapid point-of-care diagnostic Lyme disease test.
  • In recent years the company launched the critically acclaimed and award-winning LymeDiseaseAnswers.com website and Lyme Quick Takes online video series.
  • The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease, said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel.
  • As part of its collaboration, Quidel will serve as sponsor for GLAs Lyme awareness month as well as a series of educational PACE-accredited webinars.

Quidel Corp.—Developer of Only FDA-Cleared FIA Rapid Point-of-Care Diagnostic Lyme Disease Test—To Partner With Renowned Global Lyme Alliance to Dramatically Heighten Lyme Disease Awareness

Retrieved on: 
Thursday, June 9, 2022
General Health, Medical Devices, Infectious Diseases, Health, Medical Supplies, Research, Awareness, Nasdaq, Physician, FDA, Patient, Infection, COVID-19, Education, Tick-Borne Disease Alliance, Pharmaceutical industry, Vaccine, Quidel Corporation, Lyme disease

Quidel is the nations leading developer of the only rapid point-of-care diagnostic Lyme disease test.

Key Points: 
  • Quidel is the nations leading developer of the only rapid point-of-care diagnostic Lyme disease test.
  • In recent years the company launched the critically acclaimed and award-winning LymeDiseaseAnswers.com website and Lyme Quick Takes online video series.
  • The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease, said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel.
  • As part of its collaboration, Quidel will serve as sponsor for GLAs Lyme awareness month as well as a series of educational PACE-accredited webinars.

QuidelOrtho Formed by the Completion of Transaction Combining Quidel and Ortho Clinical Diagnostics

Retrieved on: 
Friday, May 27, 2022
Technology, Medical Devices, Infectious Diseases, Other Health, Biotechnology, General Health, Health, Data Management, Science, Other Science, Knowledge, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Nasdaq, Webcast, Patient, NASDAQ, IVD, Health, Automation, Nature, Commission, Immunoassay, Transfusion medicine, Conference, Interest, Terminology, Central Time Zone, Ortho Clinical Diagnostics, Security (finance), Management, Medical device, Risk management, Quidel Corporation, Ortho

QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho) announced completion of the transaction combining Quidel Corporation (Quidel) and Ortho Clinical Diagnostics Holdings plc (Ortho), creating QuidelOrtho, a leading in vitro diagnostics company.

Key Points: 
  • QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho) announced completion of the transaction combining Quidel Corporation (Quidel) and Ortho Clinical Diagnostics Holdings plc (Ortho), creating QuidelOrtho, a leading in vitro diagnostics company.
  • Under the terms of the agreement governing the transaction, former Ortho shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share.
  • Former Quidel stockholders received one share of QuidelOrtho common stock for each share of Quidel common stock.
  • The QuidelOrtho board is composed of 8 former Quidel board members and 4 former Ortho board members.

Quidel and Ortho Announce Expected Closing of Ortho Transaction

Retrieved on: 
Thursday, May 26, 2022
Form, Registrar of Companies, Food, U.S. Securities and Exchange Commission, SVC, Antibody, UK, Blood, YouTube, Terminology, Private Securities Litigation Reform Act, Twitter, Laboratory, JOINT, City Code on Takeovers and Mergers, Mergers and acquisitions, Nature, COVID-19, Failure, SAN, Food and Drug Administration, Facebook, Youth justice in England and Wales, Attention, Hospital, GLOBE, Part, Infection, Health, IVD, FDA, Efficiency, Communication, THE, LinkedIn, HIV, Security (finance), Telephone, Takeover, Patient, NASDAQ, High Court, Drug Master File, Hepatitis C, Commission, TO, Linear code, Medical device, Vaccine, Risk management, Quidel Corporation, Ortho, Nasdaq, Topco

Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq.

Key Points: 
  • Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq.
  • Under the terms of the agreement governing the transaction, Ortho shareholders will receive $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share.
  • Quidel stockholders will receive one share of QuidelOrtho common stock for each share of Quidel common stock.
  • Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022.

Quidel and Ortho Announce Expected Closing of Ortho Transaction

Retrieved on: 
Thursday, May 26, 2022
Technology, Research, Infectious Diseases, Clinical Trials, Health, Pharmaceutical, General Health, Data Management, Science, Form, Registrar of Companies, Food, U.S. Securities and Exchange Commission, SVC, Antibody, UK, Blood, YouTube, Terminology, Private Securities Litigation Reform Act, Twitter, Laboratory, JOINT, City Code on Takeovers and Mergers, Mergers and acquisitions, Nature, COVID-19, Failure, Food and Drug Administration, Facebook, Youth justice in England and Wales, Attention, Hospital, Part, Infection, Health, IVD, FDA, Efficiency, Communication, THE, LinkedIn, HIV, Security (finance), Telephone, Takeover, Corporation, Patient, NASDAQ, High Court, Drug Master File, Hepatitis C, Commission, TO, Linear code, Medical device, Vaccine, Risk management, Quidel Corporation, Ortho, Nasdaq, Topco

Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq.

Key Points: 
  • Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq.
  • Under the terms of the agreement governing the transaction, Ortho shareholders will receive $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share.
  • Quidel stockholders will receive one share of QuidelOrtho common stock for each share of Quidel common stock.
  • Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022.